In recent years, circulating tumor DNA (ctDNA) for the detection of molecular residual disease (MRD) and treatment response monitoring in solid tumors has been increasingly incorporated into clinical practice and trials.

This growing utilization has created a unique opportunity to amass and interrogate a longitudinal real-world clinico-genomics dataset of early and late-stage cancer patients, with the potential to provide drug developers and researchers with a more granular understanding of tumor biology and signals of therapy response.

In this webinar, we will discuss use cases for such a dataset and how it can support the optimization and acceleration of clinical development

Topics include:

• How real-world data can support drug development applications across biomarker discovery, clinical trial design optimization and feasibility assessment, clinical trial screening, and characterization of patient journeys
• Overview of a real-world clinico-genomics dataset containing whole-exome sequencing (WES), longitudinal monitoring of circulating tumor DNA (ctDNA), and associated clinical data (e.g., diagnosis/condition, treatment, response, and outcomes)
• Case studies & approaches leveraging real-world data and ctDNA to optimize and accelerate clinical development

Roles that will benefit the most from this webinar are those with responsibilities for:

• Early Research & Discovery
• Precision Medicine, Translational Medicine, Diagnostics, Biomarkers
• RWD/RWE/Advanced Analytics
• Bioinformatics, Data Scientists
• Clinical Development & Clinical Operations
• Medical Affairs